AbbVie
Innovative Drug Developer
Recently, a highly concerned message has been making waves in the pharmaceuticals industry: AbbVie Inc. disclosed its stance on anti-PD-(L)1×VEGFThe interest in the field of bispecific antibodies. This dynamic has once again pushed the popular track of bispecific antibodies to the forefront, attracting widespread attention within the industry.
Previously, there were rumors thatSummitThe company and AstraZeneca will reach an agreement worth150Billion-dollar cooperation$15 Billion Mega-Deal! AstraZeneca May Secure the Licensing Rights for This New Lung Cancer Drug, but this matter has recently fallen into an unsettling silence. However,SummitCompany's investors now have another attractive new possibility. Bloomberg reported a month ago,SummitThe company originates from Akeso's Evtansine (ivonescimab) caught the attention of AstraZeneca, and this drug belongs to anti-PD-(L)1×VEGFBispecific Antibody Field.
At the Q2 earnings call held on Thursday, AbbVie's Chief Scientific OfficerRoopal ThakkarRefers to this category of drugs“There are multiple assets that are continuously disclosing data over time. This is an area we are interested in and closely monitoring.”
AbbVie has always been willing to invest heavily in business expansion.Even though it claims that it will not face significant patent expirations within the next decade.
In recent years, anti-PD-(L)1×VEGFBispecific antibody assets have led to blockbuster deals for companies like Merck, Pfizer, and Bristol-Myers Squibb. However, AbbVie, like AstraZeneca and Roche, currently has no presence in this field.
AbbVie stated that a bispecific antibody, if effective across multiple indications, could be linked with its antibody-drug conjugate (ADCs) will be particularly significant when used in combination.
Meanwhile, regarding AstraZeneca andSummitThere is still no news about the cooperation of the company. Some analysts believe that it might be because AstraZeneca is unwilling to pay the relevant fees.--The leak of a potential cooperation agreement was presumably aimed at driving up the price, but AstraZeneca was unwilling to foot the bill.
AbbVie's Expression of Interest in This Field Undoubtedly Provides a Boost to the Anti-PD-(L)1×VEGFThe bispecific antibody track adds more variables, and the competitive landscape of the industry may undergo new adjustments in the future. Let's wait and see.
Reference:https://www.oncologypipeline.com/apexonco/abbvie-reveals-its-bispecific-interest
